40 – Developing cost-effective formularies: Implications for new atypical antipsychotics von Trakas, K, Diels, J, Nicholl, D, Nuyts, G

Volltext

24 – Direct healthcare costs after initiation of oral antipsychotic treatment for schizophrenia: Efficacy versus tolerability von Diels, J, Trakas, K, Nicholl, D, Nuyts, G

Volltext

23 – Analysis of psychiatric hospitalization after initiation of oral antipsychotic treatment for schizophrenia von Diels, J, Trakas, K, Nicholl, D, Nuyts, G

Volltext

The health status of obese individuals in Canada von TRAKAS, K, OH, P. I, SINGH, S, RISEBROUGH, N, SHEAR, N. H

Volltext

P.3.a.014 Assessing remission in schizophrenia patients treated with long-acting risperidone in clinical practice von Peuskens, J, Tuma, I, Pecenak, J, Eriksson, L, Bork, B, Povey, M, Jacobs, A, Trakas, K, Zhao, Z

Volltext

P.2.094 Prediction of the risk of antipsychotic-associated coronary heart disease von Trakas, K.

Volltext

Utility scores for chronic conditions in a community-dwelling population von Mittmann, N, Trakas, K, Risebrough, N, Liu, B A

Volltext

Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory von HACEK, D. M, NOSKIN, G. A, TRAKAS, K, PETERSON, L. R

Volltext

PUK5 COMPARISON OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION von Trakas, K, Robinson, K

Volltext

PMH4 EFFICACY AND SAFETY OF ORAL A TYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE von Jones, MP, Nicholl, D, Trakas, K

Volltext

Utilization of health care resources by obese Canadians von Trakas, K, Lawrence, K, Shear, N. H

Volltext

PMH47 DEVELOPING COST-EFFECTIVE FORMULARIES: IMPLICATIONS FOR NEW ATYPICAL ANTIPSYCHOTICS von Trakas, K, Diels, JK, Nicholl, D, Nuyts, G

Volltext

A minimum 5.0 ml of sputum improves the sensitivity of acid-fast smear for Mycobacterium tuberculosis von Warren, J R, Bhattacharya, M, De Almeida, K N, Trakas, K, Peterson, L R

Volltext

Risperidone long acting injection treatment in schizophrenia: 12-month results from the electronic schizophrenia treatment adherence registry (E-STAR) von Zhao, Z, Alexandrov, A, Olivares, J M, Tuma, I, Peuskens, J, Pecenak, J, Eriksson, L, Bork, B, Povey, M, Lam, A, Trakas, K

Volltext

PMH58 IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION): 6-MONTH RESULTS FROM E-STAR von Pecenak, J, Tuma, I, De groot-stam, E, Eriksson, L, Bork, B, Ligate, L, Povey, M, Lam, A, Trakas, K, Zhao, Z

Volltext

PMH4 2-YEAR OUTCOMES OF RISPERDAL® CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA von Trakas, K, Talling, D, Balshaw, R, Love, L, Robinson, K

Volltext

CS2 COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K von McGarry, LJ, Thompson, D, Knudsen, AP, Trakas, K, Cookson, JC, Weinstein, MC

Volltext

PMH12: THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA (CNOMSS) von Trakas, K, Lin, D, Balshaw, R, Robinson, K, Andrew, E

Volltext

ASSESSING LIFESTYLE DRUGS FOR DRUG BENEFIT FORMULARIES: A COST‐UTILITY ANALYSIS OF ORLISTAT AND SIBUTRAMINE FOR THE TREATMENT OF OBESITY IN ADULTS von Trakas, K, Oh, Pi, Leiter, L, Shear, Nh

Volltext

PWP4: A WILLINGNESS-TO-PAY ASSESSMENT OF TWO TREATMENTS FOR OBESITY von Trakas, K, Oh, PI, Shear, NH

Volltext